B-RAF and melanocytic neoplasia

Journal of the American Academy of Dermatology

Volumn 53, Issue 1, 2005, Pages 108-114

  Gill, Melissa ^a   Celebi, Julide Tok ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; IMATINIB; PACLITAXEL; SORAFENIB;

CARCINOGENESIS; GENE FUNCTION; GENE LOCATION; GENE MUTATION; HUMAN; MELANOMA; ONCOGENE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

HUMANS; MELANOMA; MUTATION; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 20444471400     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.04.013     Document Type: Review

References (44)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. D.S. Rigel, and J.A. Carucci Malignant melanoma: prevention, early detection, and treatment in the 21st century CA Cancer J Clin 50 2000 215 236 quiz 237-40
3. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
4. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
5. M.S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi, and R. Gerrero BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
6. V.C. Gray-Schopfer, S. da Rocha Dias, and R. Marais The role of B-RAF in melanoma Cancer Metastasis Rev 24 2005 165 183
7. K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 9 2003 6483 6488
8. N.K. Hayward Genetics of melanoma predisposition Oncogene 22 2003 3053 3062
9. K. Laud, C. Kannengiesser, M.F. Avril, A. Chompret, D. Stoppa-Lyonnet, and L. Desjardins BRAF as a melanoma susceptibility candidate gene? Cancer Res 63 2003 3061 3065
10. J. Lang, M. Boxer, and R. MacKie Absence of exon 15 BRAF germline mutations in familial melanoma Hum Mutat 21 2003 327 330
11. M. Casula, M. Colombino, M.P. Satta, A. Cossu, P.A. Ascierto, and G. Bianchi-Scarra BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study J Clin Oncol 22 2004 286 292
12. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat Rev Mol Cell Biol 5 2004 875 885
13. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
14. J. Dong, R.G. Phelps, R. Qiao, S. Yao, O. Benard, and Z. Ronai BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma Cancer Res 63 2003 3883 3885
15. A. Gorden, I. Osman, W. Gai, D. He, W. Huang, and A. Davidson Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues Cancer Res 63 2003 3955 3957
16. R. Kumar, S. Angelini, K. Czene, I. Sauroja, M. Hahka-Kemppinen, and S. Pyrhonen BRAF mutations in metastatic melanoma: a possible association with clinical outcome Clin Cancer Res 9 2003 3362 3368
17. M. Shinozaki, A. Fujimoto, D.L. Morton, and D.S. Hoon Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas Clin Cancer Res 10 2004 1753 1757
18. F. Cruz 3rd, B.P. Rubin, D. Wilson, A. Town, A. Schroeder, and A. Haley Absence of BRAF and NRAS mutations in uveal melanoma Cancer Res 63 2003 5761 5766
19. D. Rimoldi, S. Salvi, D. Lienard, F.J. Lejeune, D. Speiser, and L. Zografos Lack of BRAF mutations in uveal melanoma Cancer Res 63 2003 5712 5715
20. Y. Cohen, E. Rosenbaum, S. Begum, D. Goldenberg, C. Esche, and O. Lavie Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites Clin Cancer Res 10 2004 3444 3447
21. R.H. Edwards, M.R. Ward, H. Wu, C.A. Medina, M.S. Brose, and P. Volpe Absence of BRAF mutations in UV-protected mucosal melanomas J Med Genet 41 2004 270 272
22. J.L. Maldonado, J. Fridlyand, H. Patel, A.N. Jain, K. Busam, and T. Kageshita Determinants of BRAF mutations in primary melanomas J Natl Cancer Inst 95 2003 1878 1890
23. J.M. Davison, E. Rosenbaum, T.L. Barrett, D. Goldenberg, M.O. Hoque, and D. Sidransky Absence of V599E BRAF mutations in desmoplastic melanomas Cancer 103 2005 788 792
24. M. Gill, J. Cohen, N. Renwick, J.M. Mones, D.N. Silvers, and J.T. Celebi Genetic similarities between Spitz nevus and Spitzoid melanoma in children Cancer 101 2004 2636 2640
25. N.E. Thomas, A. Alexander, S.N. Edmiston, E. Parrish, R.C. Millikan, and M. Berwick Tandem BRAF mutations in primary invasive melanomas J Invest Dermatol 122 2004 1245 1250
26. R. Kumar, S. Angelini, and K. Hemminki Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 Oncogene 22 2003 9217 9224
27. R. Kumar, S. Angelini, E. Snellman, and K. Hemminki BRAF mutations are common somatic events in melanocytic nevi J Invest Dermatol 122 2004 342 348
28. W. Stolz, C. Schmoeckel, M. Landthaler, and O. Braun-Falco Association of early malignant melanoma with nevocytic nevi Cancer 63 1989 550 555
29. A.S. Yazdi, G. Palmedo, M.J. Flaig, U. Puchta, A. Reckwerth, and A. Rutten Mutations of the BRAF gene in benign and malignant melanocytic lesions J Invest Dermatol 121 2003 1160 1162
30. R. Loewe, H. Kittler, G. Fischer, I. Fae, K. Wolff, and P. Petzelbauer BRAF kinase gene V599E mutation in growing melanocytic lesions J Invest Dermatol 123 2004 733 736
31. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu Rev Immunol 22 2004 247 306
32. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P.N. Rao Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
33. M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon, and F. Friedlos B-RAF is a therapeutic target in melanoma Oncogene 23 2004 6292 6298
34. D.A. Tuveson, B.L. Weber, and M. Herlyn BRAF as a potential therapeutic target in melanoma and other malignancies Cancer Cell 4 2003 95 98
35. D. Strumberg, H. Richly, R.A. Hilger, N. Schleucher, S. Korfee, and M. Tewes Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 2005 965 972
36. T. Ahmad, R. Marais, M. Pyle, B. James, M. Shwartz, and M. Gore BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience J Clin Oncol 22 2004 7506
37. K.T. Flaherty, M. Brose, L. Schuchter, D.A. Tuveson, R. Lee, and B. Schwartz Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma J Clin Oncol 22 2004 7507
38. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
39. J.S. Sebolt-Leopold, and R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 2004 937 947
40. P.M. Pollock, U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, and C.M. Robbins High frequency of BRAF mutations in nevi Nat Genet 33 2003 19 20
41. Y. Sasaki, C. Niu, R. Makino, C. Kudo, C. Sun, and H. Watanabe BRAF point mutations in primary melanoma show different prevalences by subtype J Invest Dermatol 123 2004 177 183
42. M. Gill, N. Renwick, D.N. Silvers, and J.T. Celebi Lack of BRAF mutations in Spitz nevi J Invest Dermatol 122 2004 1325 1326
43. P. Uribe, Wistuba II, and S. Gonzalez BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin Am J Dermatopathol 25 2003 365 370
44. G. Saldanha, D. Purnell, A. Fletcher, L. Potter, A. Gillies, and J.H. Pringle High BRAF mutation frequency does not characterize all melanocytic tumor types Int J Cancer 111 2004 705 710